Last reviewed · How we verify
IXIFI (INFLIXIMAB-QBTX)
IXIFI (generic name: INFLIXIMAB-QBTX) is a drug developed by PFIZER INC. It is currently FDA-approved for Ankylosing spondylitis, Behcet's disease, Crohn's disease.
IXIFI is a drug that targets tumor necrosis factor, specifically inhibiting TNF-alpha. It is being studied in clinical trials for various conditions, including immune-related colitis, melanoma, and skin cancer, and is administered as an antibody.
At a glance
| Generic name | INFLIXIMAB-QBTX |
|---|---|
| Sponsor | PFIZER INC |
| Target | Tumor necrosis factor |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Ankylosing spondylitis
- Behcet's disease
- Crohn's disease
- Erythrodermic psoriasis
- Plaque psoriasis
- Psoriasis with arthropathy
- Pustular psoriasis
- Rheumatoid arthritis
- Ulcerative colitis
Common side effects
Key clinical trials
- Phase II Study of Infliximab for the Treatment of Immune Checkpoint Inhibitor Colitis (Phase 2)
- A Phase II Study of PD-1 Blockade With or Without LAG-3 Inhibition in Combination With Infliximab for the Treatment of Metastatic Melanoma and Prevention of Adverse Events (Phase 2)
- Precise Infliximab Exposure and Pharmacodynamic Control to Achieve Deep Remission in Pediatric Crohn's Disease (Phase 2)
- EPIC - A Phase 2, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Extracorporeal Photopheresis (ECP) Versus Best Available Therapy (BAT) in (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IXIFI CI brief — competitive landscape report
- IXIFI updates RSS · CI watch RSS
- PFIZER INC portfolio CI
Frequently asked questions about IXIFI
What is IXIFI?
What is IXIFI used for?
Who makes IXIFI?
What is the generic name of IXIFI?
What development phase is IXIFI in?
What does IXIFI target?
Related
- Target: All drugs targeting Tumor necrosis factor
- Manufacturer: PFIZER INC — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Ankylosing spondylitis
- Indication: Drugs for Behcet's disease
- Indication: Drugs for Crohn's disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing